An observational study in Tricuspid Regurgitation, sponsored by Edwards Lifesciences. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Edwards Lifesciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences — 3 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Edwards Lifesciences.
Among the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, this one is the only one that started in 2025, is one of 5 observational ones, and was the 13th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →3 of the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences are open now, in 7 countries. Recruiting first, the newest first:
Edwards Lifesciences · Sites in Germany, Greece, Italy and 3 more countries
Edwards Lifesciences · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 2,044 is above the median of 225 across 96 observational studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 65 across the 9 interventional studies, 500 across the 5 observational. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Edwards Lifesciences is the lead sponsor of 128 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 33 (94%) have results posted.
1 of the studies in Tricuspid Valve Insufficiency by Edwards Lifesciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03382457Edwards LifesciencesClinical Study of Edwards Cardioband FIT Valve Repair System | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.
This is a retrospective, non-randomized cohort study measuring 2-year effectiveness of the EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) system in the real-world.
This study will retrospectively evaluate EVOQUE treated patients in the STS/ACC TVT Registry who have at least severe Tricuspid Regurgitation and can be deterministically linked with Medicare data.
This group will be compared to Medicare eligible and EVOQUE eligible patients evaluated in a standard of care setting from a commercial claims database linked with electronic health records.
We will evaluate the primary outcome measure in various subgroups.
There will be continued access enrollment after the primary completion date.
Medicare eligible real-world patients with severe, symptomatic tricuspid regurgitation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation
Exclusion Criteria:
Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with less than severe Tricuspid Regurgitation
Medicare patients with at least severe Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement with the EVOQUE device and is identified in the TVT Registry
Other: EVOQUE
Medicare eligible patients with severe, symptomatic Tricuspid Regurgitation that are identifiable in a commercial claims database linked with electronic health records.
This is a retrospective, non-randomized study. The decision to intervene by TTVR with the EVOQUE device is made by the heart team.
Composite (All-Cause Death or Heart Failure Hospitalization)
Time to death or heart failure hospitalization after time zero
Time frame: 2 years
Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →